Rein Therapeutics, Inc. Financials
Financial Health Signals
Rein Therapeutics, Inc. passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Rein Therapeutics, Inc. generates $0.35 in operating cash flow (-$22.3M OCF vs -$62.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Rein Therapeutics, Inc. (RNTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Rein Therapeutics, Inc. generated $0 in revenue in fiscal year 2024.
Rein Therapeutics, Inc.'s EBITDA was -$65.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 302.6% from the prior year.
Rein Therapeutics, Inc. reported -$62.9M in net income in fiscal year 2024. This represents a decrease of 299.7% from the prior year.
Rein Therapeutics, Inc. earned $-3.51 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 2.6% from the prior year.
Rein Therapeutics, Inc. held $12.9M in cash against $0 in long-term debt as of fiscal year 2024.
Rein Therapeutics, Inc. paid $0.00 per share in dividends in fiscal year 2024.
Rein Therapeutics, Inc. had 22M shares outstanding in fiscal year 2024. This represents an increase of 343.5% from the prior year.
Rein Therapeutics, Inc. invested $14.2M in research and development in fiscal year 2024. This represents an increase of 257.0% from the prior year.
RNTX Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $1.7M-60.8% | $4.3M+40.5% | $3.1M-8.1% | $3.3M-11.2% | $3.7M+8.0% | $3.5M+75.6% | $2.0M+8863.6% | $22K |
| SG&A Expenses | $3.8M+47.8% | $2.6M+0.9% | $2.6M+3.2% | $2.5M-53.3% | $5.3M+41.6% | $3.7M-29.8% | $5.3M+172.6% | $2.0M |
| Operating Income | -$5.5M+20.1% | -$6.9M-22.5% | -$5.6M+86.9% | -$42.8M-373.5% | -$9.0M-25.5% | -$7.2M+1.2% | -$7.3M-267.6% | -$2.0M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$5.6M+18.2% | -$6.8M-24.0% | -$5.5M+86.6% | -$41.0M-358.3% | -$8.9M-25.7% | -$7.1M+3.1% | -$7.3M-301.7% | -$1.8M |
| EPS (Diluted) | $-0.21+25.0% | $-0.28-12.0% | $-0.25+87.0% | $-1.93-328.9% | $-0.45+47.7% | $-0.86 | $-1.58-295.0% | $-0.40 |
RNTX Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $53.7M-6.6% | $57.5M-0.3% | $57.6M-7.3% | $62.2M-43.2% | $109.4M+10.3% | $99.2M-6.4% | $106.0M+726.8% | $12.8M |
| Current Assets | $5.2M-21.6% | $6.6M-20.8% | $8.3M-39.0% | $13.7M-41.0% | $23.2M+81.4% | $12.8M-30.1% | $18.3M+42.8% | $12.8M |
| Cash & Equivalents | $4.0M-29.3% | $5.7M-23.0% | $7.4M-42.3% | $12.9M-41.3% | $21.9M+82.0% | $12.0M-30.4% | $17.3M+43.5% | $12.1M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $6.3M0.0% | $6.3M0.0% | $6.3M0.0% | $6.3M0.0% | $6.3M0.0% | $6.3M0.0% | $6.3M | N/A |
| Total Liabilities | $7.5M-20.6% | $9.5M+22.2% | $7.7M-0.6% | $7.8M-6.9% | $8.4M+6.6% | $7.9M+1.9% | $7.7M+374.8% | $1.6M |
| Current Liabilities | $5.7M-25.3% | $7.7M+28.7% | $6.0M+4.0% | $5.7M+16.4% | $4.9M+8.9% | $4.5M+3.4% | $4.4M+170.0% | $1.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $46.2M-3.8% | $48.0M-3.7% | $49.9M-8.3% | $54.4M-46.2% | $101.0M+10.6% | $91.3M-7.1% | $98.3M+777.8% | $11.2M |
| Retained Earnings | -$369.3M-1.5% | -$363.7M-1.9% | -$356.9M-1.6% | -$351.4M-15.4% | -$304.6M-3.0% | -$295.6M-2.5% | -$288.5M-2.6% | -$281.2M |
RNTX Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.5M+44.7% | -$6.4M-3.9% | -$6.2M-28.3% | -$4.8M+42.6% | -$8.4M-59.2% | -$5.3M+49.3% | -$10.4M-533.6% | -$1.6M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | $0 | $0 | $0+100.0% | -$96K-117.7% | $542K |
| Financing Cash Flow | $1.9M-59.7% | $4.7M+538.5% | $738K+73700.0% | $1K-100.0% | $18.3M | $0-100.0% | $15.8M | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
RNTX Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -10.4%+1.5pp | -11.9%-2.3pp | -9.6%+56.4pp | -65.9%-57.7pp | -8.2%-1.0pp | -7.2%-0.3pp | -6.9%+7.3pp | -14.2% |
| Current Ratio | 0.90+0.0 | 0.86-0.5 | 1.39-1.0 | 2.38-2.3 | 4.69+1.9 | 2.82-1.3 | 4.17-3.7 | 7.88 |
| Debt-to-Equity | 0.16-0.0 | 0.20+0.0 | 0.16+0.0 | 0.14+0.1 | 0.080.0 | 0.090.0 | 0.08-0.1 | 0.14 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Rein Therapeutics, Inc.'s annual revenue?
Rein Therapeutics, Inc. (RNTX) reported $0 in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Rein Therapeutics, Inc. profitable?
No, Rein Therapeutics, Inc. (RNTX) reported a net income of -$62.9M in fiscal year 2024.
What is Rein Therapeutics, Inc.'s earnings per share (EPS)?
Rein Therapeutics, Inc. (RNTX) reported diluted earnings per share of $-3.51 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Rein Therapeutics, Inc.'s EBITDA?
Rein Therapeutics, Inc. (RNTX) had EBITDA of -$65.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Rein Therapeutics, Inc.'s operating cash flow?
Rein Therapeutics, Inc. (RNTX) generated -$22.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Rein Therapeutics, Inc.'s total assets?
Rein Therapeutics, Inc. (RNTX) had $62.2M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Rein Therapeutics, Inc. spend on research and development?
Rein Therapeutics, Inc. (RNTX) invested $14.2M in research and development during fiscal year 2024.
How many shares does Rein Therapeutics, Inc. have outstanding?
Rein Therapeutics, Inc. (RNTX) had 22M shares outstanding as of fiscal year 2024.
What is Rein Therapeutics, Inc.'s current ratio?
Rein Therapeutics, Inc. (RNTX) had a current ratio of 2.38 as of fiscal year 2024, which is generally considered healthy.
What is Rein Therapeutics, Inc.'s debt-to-equity ratio?
Rein Therapeutics, Inc. (RNTX) had a debt-to-equity ratio of 0.14 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Rein Therapeutics, Inc.'s return on assets (ROA)?
Rein Therapeutics, Inc. (RNTX) had a return on assets of -101.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Rein Therapeutics, Inc.'s cash runway?
Based on fiscal year 2024 data, Rein Therapeutics, Inc. (RNTX) had $12.9M in cash against an annual operating cash burn of $22.3M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Rein Therapeutics, Inc.'s Piotroski F-Score?
Rein Therapeutics, Inc. (RNTX) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Rein Therapeutics, Inc.'s earnings high quality?
Rein Therapeutics, Inc. (RNTX) has an earnings quality ratio of 0.35x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.